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(left to right)doi:10.1016/j.jtcvs.2004.12.019Objective: Recent studies show beneficial long-term effects of restrictive mitral
annuloplasty in patients with end-stage heart failure. However, concerns are raised
about possible adverse effects on early postoperative systolic and diastolic function,
which might limit application of this approach in patients with heart failure.
Therefore we evaluated the acute effects of restrictive mitral annuloplasty on left
ventricular function by using load-independent pressure-volume relations.
Methods: In 23 patients (heart failure, n  10; control, n  13) we determined left
ventricular systolic and diastolic function before and after surgical intervention by
means of pressure-volume analysis with a conductance catheter. All patients with
heart failure underwent stringent restrictive mitral annuloplasty (2 sizes smaller than
the measured size), and 4 received additional coronary artery bypass grafting.
Transesophageal echocardiography was used for evaluation of valve repair. Patients
with preserved left ventricular function who underwent isolated coronary artery
bypass grafting served as control subjects.
Results: Restrictive mitral annuloplasty (ring size, 25  1) restored leaflet coapta-
tion (8.0  0.2 mm) with normal pressure gradients (2.9  1.8 mm Hg). Restrictive
mitral annuloplasty did not change cardiac output (5.0  1.8 to 5.3  0.9 L/min, P
 .516), left ventricular ejection fraction (29%  5% to 32%  8%, P  .315), or
end-systolic elastance (0.86  0.50 to 0.99  1.05 mm Hg/mL, P  .688). After
restrictive mitral annuloplasty, end-diastolic volume tended to decrease (237  89
to 226 52 mL, P .564), whereas end-diastolic pressure remained unchanged (14
 6 to 15  5 mm Hg, P  .356). Diastolic chamber stiffness tended to increase
(0.027  0.035 to 0.041  0.047 mL1, P  .542) but not significantly. Peak left
ventricular wall stress was unchanged (356  91 to 346  85 mm Hg, P  .668).
Baseline values in the control group were different, but changes in most parameters
after surgical intervention showed similar nonsignificant trends.
Conclusion: Mitral valve repair by means of restrictive mitral annuloplasty effec-
tively restores mitral valve competence without inducing significant acute changes
in left ventricular systolic or diastolic function in patients with end-stage heart
failure.
Chronic mitral regurgitation is a serious complication in patients with end-stage heart failure (HF). Patients with mitral regurgitation have a signifi-cantly decreased survival at 2 years’ follow-up versus patients without
mitral regurgitation.1
The mechanism of mitral regurgitation in end-stage HF is multifactorial. Briefly,
it is related to changes in left ventricular (LV) geometry, with a subsequent
displacement of the subvalvular apparatus, annular dilatation,2 and restrictive leaflet
motion (class IIIb according to Carpentier’s classification),3 which results in coap-
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regurgitation in these patients will lead to LV overload and
reduction of forward stroke volume. This occurs initially in
response to exercise and subsequently at rest, which in turn
activates systemic and local neurohormonal systems and
cytokines that worsen cardiac loading conditions and pro-
mote LV remodeling and dysfunction.6 This might create a
vicious circle wherein regurgitation begets more regurgita-
tion.
Previous studies have shown that interrupting this vi-
cious cycle with mitral valve repair is safe and improves
clinical outcome.7 Several groups advocate the use of a
stringent restrictive ring, 2 sizes smaller than the measured
size, to achieve better leaflet coaptation and possibly pre-
vent recurrence of mitral regurgitation and promote reverse
remodeling.8 Midterm results (18 months’ follow-up) with
this approach indicate reverse remodeling in 58% of pa-
tients.9 However, the acute effects of restrictive mitral an-
nuloplasty (RMA) on LV systolic and diastolic function in
patients with end-stage HF are unknown. There are con-
cerns that correction of mitral regurgitation might decrease
LV systolic function in the acute phase as a result of
afterload increase caused by closure of a low-resistance
runoff into the left atrium. In addition, it has been suggested
that undersizing the mitral annulus might affect LV con-
tractility because of increased mechanical tension on the
base of the heart.10 With regard to diastolic function, RMA
might impair filling. In contrast, Bolling and colleagues11
hypothesized that undersizing the mitral annulus will lead to
acute beneficial geometric changes of the base of the left
ventricle, which might reduce LV volume and wall stress.
The purpose of this study was therefore to quantify the acute
effects of RMA on global and intrinsic LV systolic and
diastolic function in these patients.
Material and Methods
A total of 23 patients were studied in the operating room before
and after cardiopulmonary bypass (CPB) by using pressure-vol-
ume analysis with the conductance catheter method. We included
10 patients with end-stage HF and coexistent severe mitral regur-
gitation who underwent mitral valve repair by means of stringent
restrictive annuloplasty and 13 control patients with preserved LV
function who underwent elective coronary artery bypass grafting
(CABG). The control group was used to distinguish the effects of
mitral annuloplasty from the effects of CPB and cardioplegic
cardiac arrest per se. In both groups surgical intervention was
performed during normothermic CPB with intermittent antegrade
warm blood cardioplegia. The study protocol was approved by the
institutional review board, and all patients provided informed
written consent.
Patient Selection and Echocardiographic Criteria
The patients in the RMA group fulfilled the following criteria:
1. New York Heart Association class III or IV was present.
2. LV ejection fraction (LVEF) of less than 30% was present.
34 The Journal of Thoracic and Cardiovascular Surgery ● July 23. Mitral regurgitation of grade 2 or greater, as assessed by
means of transesophageal echocardiography (TEE) preop-
eratively (without general anesthesia to avoid underestima-
tion of the severity of the mitral regurgitation): The severity
of mitral regurgitation was graded semiquantitatively on the
basis of color-flow Doppler scanning and characterized as
mild (1; jet area/left atrial area of 10%), moderate (2;
jet area/left atrial area of 10%-20%), moderately severe
(3; jet area/left atrial area of 20%-45%), and severe (4;
jet area/left atrial area of 45%).12 In patients with mitral
regurgitation grade 2, an intraoperative dynamic loading
test was performed, as described by Dion.5 If the result of
this test was positive (ie, if it resulted in a definite worsen-
ing of the severity of mitral regurgitation), RMA was per-
formed.
4. The mechanism of mitral regurgitation was based on mal-
coaptation caused by systolic restrictive motion of the mi-
tral leaflets.
5. Maximal medical therapy for HF, including diuretics, af-
terload reduction, and -blocking agents, was in use.
Patients with primary mitral valve dysfunction (mitral valve
prolapse, rheumatic valve disease, and mitral valve stenosis) were
excluded from the study. Also, patients with a previously im-
planted biologic or mechanical prosthesis in the aortic position
were not included in this study.
The control group was recruited from patients with preserved
LV function (LVEF 40%) who underwent elective CABG for
multivessel coronary artery disease and who needed no additional
valvular operations. The characteristics of both groups are sum-
marized in Table 1.
Anesthesia
All patients received total intravenous anesthesia with target-
controlled infusion of propofol, remifentanil, and sufentanil. Hyp-
notic state was monitored with a Bispectral Index monitor (Aspect
Medical Systems, Newton, Mass). A single dose of pancuronium
bromide (0.1 mg/kg) was given to facilitate intubation. During the
operation, the propofol concentration was adjusted between 1.5
and 2.0 g/mL to maintain a Bispectral Index value of less than
60. Remifentanil was titrated between 5 and 10 ng/mL in response
to the patient’s hemodynamic reaction to surgical stimuli. Sufen-
tanil was started at a targeted concentration of 0.1 ng/mL after the
start of the operation to allow smooth transition of the patient’s
analgesic state from the operating room to the intensive care unit.
The patients were ventilated with an oxygen-air mixture (fraction
of inspired oxygen of 40%) at a ventilatory rate of 12 to 15
breaths/min, and ventilatory volume was adjusted to maintain
normal PaCO2. A thermal filament catheter was placed in the
pulmonary artery through the right internal jugular vein for semi-
continuous thermodilution cardiac output measurements (Edwards
Lifesciences, Uden, The Netherlands). A multiplane TEE probe
was inserted to facilitate positioning of the conductance catheter
and to evaluate the effects of mitral valve repair. We anticipated
that the patients with HF would require inotropic support after
surgical intervention. Because this would bias our LV function
measurements, we started inotropic support directly after induction
of anesthesia, with a low loading dose of 0.25 mg/kg enoximone in
10 minutes, and thereafter we provided continuous infusion at a
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whole operation.
Surgical Techniques
After median sternotomy and, if indicated, harvesting of bypass
material, the pericardium was opened, and normothermic CPB was
instituted with intermittent antegrade warm blood cardioplegic
arrest.13 After completion of the anastomosis, a stringent RMA
was performed through a transseptal approach by using a Carpen-
tier Edwards Physio-ring (Edwards Lifesciences).14 The ring size
was determined by measuring the size of the anterior mitral leaflet,
and a ring 2 sizes smaller than the measured size was implanted.
After weaning from CPB, TEE evaluation was immediately per-
formed in all patients to assess residual mitral regurgitation, trans-
mitral diastolic pressure gradient (determined from continuous-
wave Doppler), and length of coaptation of the leaflets.
Study Protocol
Before and directly after CPB, conductance catheter measure-
ments were performed, as described previously.15 Briefly, tem-
porary epicardial pacemaker wires were placed on the right
atrium to enable pre-CPB and post-CPB measurements at fixed
equal heart rates. A tourniquet was placed around the inferior
vena cava to enable temporary preload reductions. An 8F sheath
was placed in the ascending aorta for introduction of the con-
ductance catheter. The conductance catheter was introduced
under TEE guidance and placed along the long axis of the LV.
The position was optimized through inspection of the segmental
volume signals. Conductance catheter calibration was per-
formed before and after CPB by using calibration factor ,
derived from thermodilution, and parallel conductance correc-
tion volume, determined by using the hypertonic saline meth-
od.16 At each stage, we performed at least 2 injections of 7 mL
of 10% saline into the pulmonary artery through the distal port
of the thermodilution catheter. Continuous LV pressure and
volume signals derived from the conductance catheter were
displayed and acquired at a 250-Hz sampling rate with a Ley-
com CFL-512 (CD Leycom, Zoetermeer, The Netherlands).
Data were acquired during steady-state conditions and during
temporary caval vein occlusion, all with the ventilator turned
off at end expiration. Acquisition was performed at a fixed atrial
pacing rate of 80 beats/min. From these signals, hemodynamic
indices were derived as described below.
Pressure-volume Analysis
Global LV function. Parameters of global systolic and dia-
stolic function (heart rate, cardiac output, stroke volume, stroke
work, pressure-volume area, LVEF, dP/dtMAX, dP/dtMIN, end-
diastolic volume [EDV], end-systolic volume [ESV], end-diastolic
pressure [EDP], end-systolic pressure [ESP], and relaxation con-
stant Tau) were calculated from steady-state beats by using cus-
tom-made software. Mechanical dyssynchrony and internal flow
fraction were calculated as previously described.17 Effective arte-
rial elastance, a measure of afterload, was calculated as ESP/SV.
Time-varying wall stress, WS(t), was calculated from the LV
pressure and volume signals (P[t], V[t]), as described by Arts and
associates18:
The Journal of ThoracWS(t) P(t) · [1 3 · V(t) ⁄ VWALL]. (1)
LV wall volume was estimated on the basis of the diastolic
posterior wall thickness derived from M-mode echocardiography.
The gradient across the LV outflow tract was calculated as the
difference between peak LV pressure and peak aortic pressure.
Systolic and diastolic LV pressure-volume relations. Systolic
function was characterized by the slope of the end-systolic pres-
sure-volume relation (end-systolic elastance), the slope of the
relation between the dP/dtMAX and EDV, and the slope of the
preload recruitable stroke work relation. The position of the end-
systolic pressure-volume relation was quantified by calculating the
ESV intercept at a fixed ESP. The position of the dP/dtMAX–EDV
relation was determined by calculating the intercept at a fixed
EDV; this index is denoted as dP/dtMAX,IND. Similarly, the posi-
tion of the preload recruitable stroke work relation was determined
by calculating the intercept at a fixed EDV, SWIND. As previously
described,19 the fixed ESP and EDV levels were set retrospectively
as the mean ESP and EDV in each group. Diastolic chamber
stiffness was quantified by means of exponential regression of the
end-diastolic pressure-volume relation.20,21
Statistical Analysis
Pre- and post-CPB data were compared with paired t tests. All data
are presented as the mean  standard deviation.
Results
All patients with HF were successfully weaned from CPB
after successful mitral valve repair.
In 6 patients the origin of HF was ischemic, and in 4 the
origin was nonischemic. In 4 ischemic patients additional
CABG was performed; the other 2 patients had irreversible
ischemia and did not receive CABG. In 3 patients with
severe tricuspid regurgitation, a concomitant restrictive tri-
cuspid ring annuloplasty (ring size, 26) was performed. Six
(60%) patients required inotropic support more than 24
hours postoperatively. However, none of the patients re-
quired intra-aortic balloon pump support. The median stay
in the intensive care unit in this group was 4 days (range,
2-7 days), with a median total hospital stay of 14 days
(range, 7-18 days). All patients could be discharged in good
clinical condition from the hospital. The surgical details of
TABLE 1. Patient characteristics
RMA group Control group
No. of patients 10 13
Male/female sex 5/5 11/2
Age (y) 56 18 63  8
NYHA class 3.6 0.5 
LVEF (%) 25 5 58  9
Mitral regurgitation (grade) 3.3 0.5 
RMA, Restrictive mitral annuloplasty; NYHA, New York Heart Association;
LVEF, left ventricular ejection fraction.both groups are summarized in Table 2.
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Mitral regurgitation quantified before the operation was due
to annular dilation and systolic restrictive motion of the
mitral leaflets and was grade 3 or greater in all patients.
After weaning from CPB, intraoperative TEE showed a
mean length of coaptation of 8  2 mm, without residual
mitral regurgitation (Table 2 and Figure 1). The mean
transmitral diastolic pressure gradient was 2.9 1.8 mm Hg
(range, 1.2-7.5 mm Hg). None of the patients showed sys-
tolic anterior movement of the anterior leaflet.
Hemodynamic Indices in the RMA and Control
Groups
Data on hemodynamic indices in the RMA and control
groups are shown in Table 3. Cardiac output and LVEF
remained unchanged after RMA. ESV and EDV tended to
decrease, but these changes did not reach statistical signif-
icance. The active relaxation (Tau) was significantly im-
proved, from 73  18 to 63  15 ms (P  .047). End-
diastolic pressure did not increase significantly, and dP/
dtMAX, dP/dtMIN, and stroke work were also unchanged.
Effective arterial elastance (a measure of afterload) was
unchanged after RMA. After ring insertion, the pressure
gradient across the LV outflow tract was unchanged (from
2.1  3.3 to 2.8  3.3 mm Hg, P  .662). Mechanical
dyssynchrony showed a clear tendency to decrease after
RMA, but the changes did not reach statistical significance
(P  .084). The mechanical efficiency, calculated as stroke





CPB time, median (min) 137 (range, 105-287) 104 (range, 60-167)
Aox time, median (min) 96 (range, 65-196) 75 (range, 43-129)
Pre-MR 3.3 0.5 
AM size (mm) 4.1 0.4 
AML size (mm) 2.9 0.3 
AM/AML ratio 1.4 0.2 
Ring size 25 1 
CABG
No. of patients 4 13
No. of anastomoses 3.8 1.0 3.7 0.9
Length of coaptation
(cm)
0.8  0.2 
Transmitral gradient
(mm Hg)
2.9  1.8 
ICU stay, median (d) 4 (range, 2-7) 2 (range, 1-4)
Hospital stay, median
(d)
14 (range, 7-18) 9 (range, 6-35)
RMA, Restrictive mitral annuloplasty; CPB, cardiopulmonary bypass; Aox,
aortic crossclamp; MR, mitral regurgitation; AM, mitral annulus; AML,
anterior mitral leaflet; CABG, coronary artery bypass grafting; ICU, inten-
sive care unit.work/pressure-volume area, was unchanged after RMA.
36 The Journal of Thoracic and Cardiovascular Surgery ● July 2Similarly, peak LV wall stress (356  91 to 346  85 mm
Hg, P  .668) and end-diastolic wall stress (64  30 to 68
 17 mm Hg, P  .639) were unchanged. Although base-
line values of most parameters in the control group were
substantially different from those in the RMA group (con-
sistent with the poor LV function in the RMA group), the
changes after surgical intervention were very similar. As in
the RMA group, most parameters were unchanged, except
Figure 1. Transesophageal echocardiographic long-axis view
before and after restrictive mitral annuloplasty in a 41-year-old
patient with ischemic dilated cardiomyopathy (left ventricular
ejection fraction, 20%) and severe mitral regurgitation (grade 4).
Mitral annular dilatation was demonstrated as the relative ratio
between the diastolic mitral annular diameter (5.2 mm) and the
diastolic length of the anterior mitral leaflet (3.6 mm) exceeded
1.3 (1.44). Restrictive mitral annuloplasty (Edwards Physio-ring
size 26) was performed, and postoperative mitral leaflet coapta-
tion was 12 mm, with a normal inflow pressure gradient (3.5 mm
Hg) and no residual mitral regurgitation. Additional restrictive
tricuspid ring annuloplasty was performed for severe tricuspid
regurgitation (grade 3).Tau, which was significantly improved in both groups, but
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groups (10.1  5.0 ms in the RMA group and 11.1 
5.4 ms in the control group, P  .829). As a difference,
LVEF was significantly improved in the control group (46%
 15% to 52%  18%, P  .025), whereas the increase in
the RMA group did not reach statistical significance (29%
 5% to 32%  8%, P  .315).
Pressure-volume Relations
Data on pressure-volume relations are shown in Figure 2.
Because steady-state hemodynamic indices, as reported in
the previous section, are load dependent, we also assessed
systolic and diastolic function by means of pressure-volume
relations. The slopes of these relations are sensitive and
load-independent measures of LV function. Pressure-vol-
ume relations were determined from data acquired during
temporary preload reduction obtained by means of vena
TABLE 3. Hemodynamic data before and after surgical int
RMA group (n  1
Before After
HR (beats/min) 85 7 88 13
CO (L/min) 5.0 1.8 5.3 0.9
SV (mL) 68 25 69 10
LVEF (%) 29 5 32 8
EDV (mL) 237 89 226 52
ESV (mL) 171 67 163 51
ESP (mm Hg) 78 8 79 14
EDP (mm Hg) 14 6 15 5
dP/dtMAX (mm Hg/s) 713 154 775 197
dP/dtMIN (mm Hg/s) 754 105 802 161
SW (mm Hg · mL) 4299 1335 4162 125
PVA (mm Hg · mL) 9422 3460 9072 292
SW/PVA 0.50 0.17 0.49 0.1
Tau (ms) 73 18 63 15
EA (mm Hg/mL) 1.39 0.60 1.29 0.3
DYSS (%) 23.6 4.3 18.5 6.7
IFF (%) 31.7 15.4 24.6 20.
EES (mm Hg/mL) 0.86 0.50 0.99 1.0
ESVIND (mL) 169 81 161 68
S-dP (mm Hg · s1 · mL1) 6.6  5.4 7.2 8.9
dP/dtMAX, IND (mm Hg/s) 734 633 771 264
S-PRSW (mm Hg) 64 54 60 41
SWIND (mm Hg · mL) 4693 3140 5093 370
PWS (mm Hg) 356 91 346 85
WSED (mm Hg) 64  30 68 17
KED (mL
1) 0.027 0.035 0.041 0.0
RMA, Restrictive mitral annuloplasty; CABG, coronary artery bypass grafti
ejection fraction; EDV, end-diastolic volume; ESV, end-systolic volume; ES
pressure-volume area; Tau, relaxation time constant; EA, effective arteria
end-systolic elastance; ESVIND, intercept of ESPVR at mean ESP; S-dP, slo
at mean EDV; S-PRSW, slope of the PRSW relation; SWIND, intercept of PRS
KED, diastolic chamber stiffness constant.caval occlusion. The mean reduction in EDV was 33  13
The Journal of ThoracmL in the control group and 39 16 mL in the RMA group.
In both the RMA and control groups, the slopes of the
systolic relations (end-systolic elastance, slope of the rela-
tion between the dP/dtMAX and EDV, and preload re-
cruitable stroke work relation) did not show significant
changes after surgical intervention. Baseline values con-
firmed poor LV function in the RMA group. With regard to
diastolic function, the diastolic chamber stiffness constant
increased in both groups (control: 0.021 0.014 to 0.038
0.014 mL1, P  .015; RMA: 0.027  0.035 to 0.041 
0.047 mL1, P  .542), but the increase did not reach
statistical significance in the RMA group.
Discussion
Mitral valve regurgitation is an important pathology in
end-stage HF characterized by annular dilatation and re-
ntion in the RMA and control (CABG) groups
Control group (n  13)
P value Before After P value
.491 82 3 86  8 .113
.516 4.9 1.2 5.9 1.4 .193
.905 59 15 69 19 .350
.315 46 15 52 18 .025
.564 142 52 146 45 .720
.459 86 49 82 47 .190
.706 74 13 79 14 .517
.356 8 2 14  5 .001
.444 992 282 970 137 .701
.351 880 208 954 185 .474
.703 4400 1605 5004 1827 .714
.808 5873 2079 6376 2517 .761
.826 0.75 0.06 0.80 0.10 .306
.047 62 6 51  5 .001
.546 1.27 0.20 1.22 0.38 .984
.084 17.8 4.1 17.1 2.7 .217
.459 19.4 8.6 17.2 6.3 .127
.688 1.31 0.93 1.26 0.72 .836
.572 82 50 69 37 .048
.858 8.5 5.4 7.4 4.2 .583
.832 1160 625 1129 467 .313
.855 65 30 55 20 .594
.725 5678 3532 5473 2544 .985
.668  
.639   
.542 0.021 0.014 0.038 0.019 .015
R, heart rate; CO, cardiac output; SV, stroke volume; LVEF, left ventricular
d-systolic pressure; EDP, end-diastolic pressure; SW, stroke work; PVA,
stance; DYSS, mechanical dyssynchrony; IFF, internal flow fraction; EES,
dP/dtMAX–EDV relation; dP/dtMAX, IND, intercept of dP/dtMAX–EDV relation
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associates1 clearly demonstrated that the severity of mitral
regurgitation is directly related to mortality risk.
Therefore it seems reasonable to correct mitral regurgi-
tation in patients with end-stage HF to improve prognosis.
Currently, mitral annuloplasty is not routinely performed in
these patients because substantial mortality and high recur-
rence rates are reported, and no evidence from randomized
studies is available.7,24 However, several recent studies
have shown relatively low operative mortality and suggest
improved long-term survival after stringent RMA.9,11,25 Un-
fortunately, insights in the acute effects of RMA on systolic
and diastolic LV performance are still limited, and concerns
are raised about possible adverse acute effects on systolic
and diastolic LV function, which would limit application of
this approach in patients with end-stage HF. The aim of our
study was therefore to quantify these effects by use of
load-independent pressure-volume indices.
We found unchanged systolic function after RMA. This
is interesting because earlier studies had predicted adverse
effects, which would be the result of an afterload mismatch
created by closure of a low-resistance runoff into the left
atrium. However, this “pop-off” effect might not exist, and
the high mortality in earlier studies appears mainly related
to loss of LV function by disruption of the subvalvular
apparatus because in that time, valve replacement (rather
than repair) was mostly performed.26 The effect on systolic
function might also result from acute remodeling of the base
of the heart because of the undersized ring. Bolling and
colleagues27 argue that this would improve systolic func-
Figure 2. Pressure-volume relations before and after
heart failure. In this patient the end-diastolic press
diastolic stiffness. This was also found in the group as
slope (EES) of the end-systolic pressure-volume relatio
there was a small increase in EES in the RMA group,tion; however, a study by David and coworkers28 implies a
38 The Journal of Thoracic and Cardiovascular Surgery ● July 2negative effect on systolic function because an undersized
ring presumably impairs stretching and shortening of the
proximal part of the basoconstrictor muscles (similar to a
rigid ring). In our study we did not find any evidence for an
altered (either reduced or improved) systolic function. In
addition, systolic anterior motion of the anterior leaflet
leading to LV outflow tract obstruction was not found in our
series.
With regard to diastolic function, we found an increase in
diastolic chamber stiffness. This effect was present in both
groups, but it was only statistically significant in the control
patients. This increase in diastolic chamber stiffness is prob-
ably mainly an effect of cardioplegic arrest, leading to
interstitial myocardial edema.29 LV wall stress was un-
changed after RMA, which is consistent with largely un-
changed EDV and ESP.
The number of studies in which the effects of RMA on
LV performance are evaluated is limited. Several studies
show improved LVEF and reduced EDV.8,11,25,30 Bishay
and colleagues31 reported improved LV function and re-
versed remodeling at 2 years’ follow-up in patients with
severe LV dysfunction. However, this group was heteroge-
neous, and the patients underwent either mitral annuloplasty
with various techniques or mitral valve replacement. Bax
and associates9 studied patients who strictly underwent
RMA and showed that reverse remodeling of the left ven-
tricle is a gradual and time-dependent process. These results
are consistent with our findings, which show no acute ef-
fects on LV performance after RMA. Interestingly, our
results show a clear tendency for a reduced mechanical
ctive mitral annuloplasty in a patient with end-stage
olume relation (EDPVR) demonstrates an increased
ole, but the effect was not statistically significant. The
SPVR) in this patient decreased slightly. On average,




but tdyssynchrony after RMA. This index has recently been
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and potentially this improvement might contribute to bene-
ficial long-term effects.
Limitations
The sample size in our study was relatively small, and
potentially positive effects on systolic function might be
demonstrated in a larger group of patients. However, we
performed pre- and post-CPB measurements in each patient,
which optimizes the statistical power to detect possible
effects of the surgical intervention. In addition, the RMA
group was heterogeneous because in 4 patients additional
CABG was performed. This subgroup was too small for
meaningful statistical analysis, but the effects on pressure-
volume relations in these patients did not appear to be
different compared with the effects in the whole group.
Furthermore, beneficial effects on LV systolic function in
these patients would not be expected early after surgical
intervention because the effects of revascularization on hi-
bernating myocardium often occur later after the opera-
tion.32 Measurements of global LV function were per-
formed immediately after the operation with an open chest
and during inotropic support. The confounding effects of
inotropic support were limited by also performing the mea-
surements before the operation during inotropic support, but
possible altered -receptor sensitivity cannot be excluded.
Assessment of regional function and of long-term effects
under physiologic conditions requires further study.
Conclusion
Mitral valve repair by means of RMA effectively restores
mitral valve leaflet coaptation in patients with end-stage HF
and severe mitral regurgitation, without significant acute
changes in baseline hemodynamics and LV systolic and
diastolic function. Our findings support the use of this
approach, even in patients with severely depressed LV
function, in view of the expected beneficial long-term
results.
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